Alterations and imbalances in the rheostat of neuroactive KP metabolites have been implied in a wide range of diseases and disorders, including inflammation/immune disorders, endocrine/metabolic conditions, Alzheimer’s disease, amyotrophic lateral sclerosis, Huntington’s disease, cancer, depression, and schizophrenia 7–10. Here, NPPA is linked to depressive symptom measurement.